Tokyo, May 31, 2018- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.
Particulars
- Reasons for the acquisition of own shares
Shareholder return and improvement of capital efficiency - Contents of acquisition
(1) Class of shares to be acquired: Common stock of the Company
(2) Total number of shares to be acquired: Up to 60 million shares
(The percentage compared to the total number of shares outstanding: 3.04 %)
(3) Aggregate amount of acquisition cost: Up to 100 billion yen
(4) Period of acquisition: From June 1, 2018 to September 20, 2018
(Reference)
The status of treasury shares as of March 31, 2018:
Total number of shares outstanding: 1,976,152,409 shares
Number of treasury shares: 92,670,766 shares
